Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up in Resected, EGFR-mutated NSCLC By Ogkologos - April 2, 2025 709 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an exploratory analysis of the ADAURA study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Approves Pralsetinib for Lung Cancer with RET Gene Fusions September 10, 2020 FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid... September 30, 2022 Beauty, Healing and Space January 27, 2021 Sacituzumab Govitecan Earns Full Approval for Triple-Negative Breast Cancer May 12, 2021 Load more HOT NEWS Reducing Cancer’s Global Burden: A Conversation with NCI’s Dr. Satish Gopal Checking in on our Mental Health Final OS and the Exploratory Analysis of the Outcome with Osimertinib... Patient Guide on Cancer Pain Management Now Available Also in French
